Rafferty Asset Management, LLC Voyager Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$7.42 - $10.54 $222,407 - $315,925	-29,974 Reduced 25.14%	89,242 $705,000
Q1 2024 May 13, 2024	BUY	$7.15 - $10.84 $852,394 - $1.29 Million	119,216 New	119,216 $1.11 Million
Q3 2020 Nov 13, 2020	SELL	$10.01 - $13.75 $140,190 - $192,568	-14,005 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$8.05 - $14.21 $112,740 - $199,011	14,005 New	14,005 $177,000
Q1 2020 May 15, 2020	SELL	$6.8 - $14.66 $298,377 - $643,266	-43,879 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$12.82 - $16.85 $623,628 - $819,668	-48,645 Reduced 52.58%	43,879 $612,000
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $479,872 - $832,348	29,422 Added 46.63%	92,524 $1.59 Million
Q2 2019 Aug 09, 2019	BUY	$19.18 - $27.88 $1.21 Million - $1.76 Million	63,102 New	63,102 $1.72 Million

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.